Publication | Closed Access
Nivolumab versus pembrolizumab in previously-treated advanced non-small cell lung cancer patients: A propensity-matched real-world analysis
13
Citations
15
References
2022
Year
MedicinePropensity-matched Real-world AnalysisImmune Checkpoint InhibitorNivolumab Versus PembrolizumabPharmacotherapyCancer TreatmentOncologyRadiation OncologyLung Cancer
| Year | Citations | |
|---|---|---|
Page 1
Page 1